Naveris
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 Hickory Dr Ste 600, Waltham, Massachu...Phone Number
(833) 628-3747Website
www.naveris.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Naveris
Naveris specializes in developing highly sensitive blood tests for the early detection of viral cancers, significantly improving upon traditional methods like scans and biopsies. Their flagship product, NavDx, is a liquid biopsy that utilizes proprietary technology for ultrasensitive surveillance of HPV-related cancers. The company aims to transform cancer detection and enhance patient outcomes through non-invasive testing and real-time monitoring of treatment responses. Naveris serves both patients and physicians, focusing on optimizing cancer surveillance and detecting recurrences in patients in remission.Explore more
Naveris Org Chart
Get the full picture
Sign in to uncover key details.
PP
Director, Laboratory Services, Nc Lab
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Naveris your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Naveris launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Naveris, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Naveris has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Naveris has new funding data
Earning: See what the market has to say on Naveris recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Naveris
Check out if Naveris is spiking on competitors!
Click to see if Naveris had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Naveris
Compare insights from companies similar to Naveris, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Naveris is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Naveris is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Naveris.
Naveris financials insights
Gather financial insights about Naveris, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$19M
2022
Series A
$51M
Naveris Tech Stack
A closer look at the technologies used by Naveris
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Hiring Plans
Naveris has more open roles in Marketing than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Naveris has more open roles in Sales than it has had at any time in the past 6 months.
Hiring Plans
Open Position
Naveris News & Media
Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx test for Molecular Residual Disease (MRD) detection in anal squamous cell carcinoma (ASCC) patients. NavDx, Naveris’ proprietary flagship blood test, is the first and only clinically validated circulating tumor TTMV®-HPV DNA blood test that provides a non-invasive and precise method that can detect MRD before thNaveris Announces Expanded Commercial Payor Coverage for NavDx® Test from Blue Shield of California
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Blue Shield of California, an independent licensee of the Blue Cross Blue Shield Association, provides coverage as of July 1, 2024 for the NavDx® test, Naveris’ proprietary flagship blood test for Tumor Tissue Modified Viral (TTMV®)-HPV DNA. NavDx is the first and only clinically validated circulating TTMV-HPV DNA blood test. It provides a non-invasive andNaveris to Showcase Advances in Precision Surveillance for HPV-Associated Oropharyngeal Cancer Using the NavDx® Test at the 2024 ASTRO Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place September 29 – October 2, 2024, in Washington, D.C.. These presentations will showcase the role of the NavDx® test, the first and only clinically validated circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test, in the managemNaveris Presents New Data on the NavDx® test for HPV-Associated Oropharyngeal Cancer at the 2024 AAO-HNS Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)-- #AAO2024--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 2024 Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), taking place September 28 – October 1, 2024 in Miami Beach, Florida. These presentations highlight the continued innovation of the NavDx®test , the first and only clinically validated circulating Tumor Tissue Modified Vira
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Naveris
Sign Up For FreeTo access detailed company insights
Naveris specializes in developing highly sensitive blood tests for the early detection of viral cancers, significantly improving upon traditional methods like scans and biopsies. Their flagship product, NavDx, is a liquid biopsy that utilizes proprietary technology for ultrasensitive surveillance of HPV-related cancers. The company aims to transfor... Read More
